BY ALBERT RONNING-ANDERSSON
-
GN’s US online store is still making losses – but breakeven is approaching
By late 2025 or early 2026, the listening to firm expects to have black figures on the underside line.
-
ALK eyes top sales potential from ARS license in mid-2030s after overcoming shift challenges
Not till the mid-2030s does ALK anticipate to peak potential gross sales from the nasal spray Neffy, for which the Danish firm simply purchased licensing rights in a helpful contra…
-
Novo Nordisk acquires US facility for API manufacturing
The manufacturing facility will certainly create energetic components for “future Novo Nordisk items”.
-
Novo Nordisk acquires US facility for API manufacturing
The factory will produce active ingredients for “future Novo Nordisk products”.
-
CEO sees a way for GN around Trump’s tariff wall
In 2023, GN produced 38% of complete earnings in The United States and Canada.
-
Demant on presidential election: “The world is a better place without trade restrictions”
It would certainly be harmful to the globe in its entirety if the United States enforces the tolls on products from various other nations revealed by governmental prospect Donald T…
-
Spero Therapeutics fails midway – reduces workforce by 39%
United States biotech business Spero Rehabs scraps prospect after stopped working Stage II test.
-
New biotech company aims to commercialize research in bottled exercise
A number of experts are doubtful.
-
Vestager fines Teva EUR 463 million for systematic attempts to block competition
With defamation of characters and misuse of the license system, Teva methodically attempted to obstruct competitors for the medication Copaxone when the license will end, according…
-
Lundbeck’s bid for Longboard had rivals
As early as December 2023, Lundbeck spoken to Longboard’s chief executive officer to check out collaboration possibilities, according to records submitted with the United Sta…
